STOCK TITAN

Seres Therapeutics (MCRB) director receives 6,500 stock options at $7.14 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Seres Therapeutics, Inc. director Dennis A. Ausiello received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. The options vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual stockholder meeting occurring after July 8, 2026, and expire on July 7, 2036. Following this grant, he holds 6,500 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider Ausiello Dennis A
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 6,500 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 6,500 shares (Direct)
Footnotes (1)
  1. [object Object]
Option shares granted 6,500 shares Stock Option (right to buy) grant to director Dennis A. Ausiello on July 8, 2026
Exercise price $7.14 per share Conversion or exercise price for the 6,500 stock options granted
Expiration date July 7, 2036 Expiration of the 6,500 stock options if not exercised earlier
Shares underlying options 6,500 shares Each option represents the right to buy one share of common stock
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 7.1400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests and becomes exercisable financial
"The option vests and becomes exercisable on the earlier to occur of"
expiration date financial
"expiration_date: 2036-07-07T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Seres Therapeutics (MCRB) director Dennis Ausiello report on this Form 4?

Director Dennis A. Ausiello reported a grant of stock options for 6,500 shares of Seres Therapeutics common stock at an exercise price of $7.14 per share as director compensation.

What is the exercise price of the new stock options reported for MCRB?

The granted stock options have an exercise price of $7.14 per share. This is the price at which Dennis A. Ausiello can purchase Seres Therapeutics common stock once the options vest.

When do Dennis Ausiello’s new Seres Therapeutics (MCRB) options vest?

The options vest on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026, according to the grant terms.

How many Seres Therapeutics (MCRB) options does Dennis Ausiello hold after this transaction?

After this grant, Dennis A. Ausiello beneficially holds 6,500 stock options directly, each representing the right to acquire one share of Seres Therapeutics common stock upon exercise.

What is the expiration date of the Seres Therapeutics (MCRB) options granted to Dennis Ausiello?

The granted stock options expire on July 7, 2036. After this date, any unexercised options will no longer be exercisable for Seres Therapeutics common stock.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ausiello Dennis A

(Last)(First)(Middle)
C/O SERES THERAPEUTICS, INC.
101 CAMBRIDGE PARK DRIVE

(Street)
CAMBRIDGE MASSACHUSETTS 02140

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$7.1407/08/2026A6,500 (1)07/07/2036Common Stock6,500$06,500D
Explanation of Responses:
1. The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.
/s/ Thomas J. DesRosier, Attorney-in-Fact07/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)